Large genomic deletions inactivate the BRCA2 gene in breast cancer families

J Med Genet. 2005 Oct;42(10):e64. doi: 10.1136/jmg.2005.032789.

Abstract

Background: BRCA1 and BRCA2 are the two major genes responsible for the breast and ovarian cancers that cluster in families with a genetically determined predisposition. However, regardless of the mutation detection method employed, the percentage of families without identifiable alterations of these genes exceeds 50%, even when applying stringent criteria for family selection. A small but significant increase in mutation detection rate has resulted from the discovery of large genomic alterations in BRCA1. A few studies have addressed the question of whether BRCA2 might be inactivated by the same kinds of alteration, but most were either done on a relatively small number of samples or employed cumbersome mutation detection methods of variable sensitivity.

Objective: To analyse 121 highly selected families using the recently available BRCA2 multiplex ligation dependent probe amplification (MLPA) technique.

Results: Three different large genomic deletions were identified and confirmed by analysis of the mutant transcript and genomic characterisation of the breakpoints.

Conclusions: Contrary to initial suggestions, the presence of BRCA2 genomic rearrangements is worth investigating in high risk breast or ovarian cancer families.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • BRCA2 Protein / genetics*
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Cloning, Molecular
  • DNA Mutational Analysis
  • Exons
  • Female
  • Gene Deletion*
  • Genetic Predisposition to Disease
  • Genetic Testing / methods*
  • Genome*
  • Humans
  • Models, Genetic
  • Molecular Sequence Data
  • Recombination, Genetic

Substances

  • BRCA2 Protein

Associated data

  • GENBANK/AY436640
  • OMIM/113705
  • OMIM/600185
  • RefSeq/NM_000059